Kidney injury biomarkers during exposure to tenofovir-based preexposure prophylaxis.
Kidney injury biomarkers during exposure to tenofovir-based preexposure prophylaxis.
复制标题
DOI：
10.1097/qad.0000000000002865
复制
发表时间：
2021-06-01
期刊：
影响因子：
--
通讯作者：
Partners PrEP Study Team
中科院分区：
文献类型：
--
作者：
Nickolas TL;Barasch J;Mugwanya KK;Branch AD;Heffron R;Wanga V;Mugo NR;Ronald A;Celum C;Donnell D;Baeten JM;Wyatt CM;Partners PrEP Study Team
我们之前报道了随机接受恩曲他滨/富马酸替诺福韦酯暴露前预防（FTC/TDF PrEP）的HIV阴性成人与安慰剂相比，非白蛋白蛋白尿的发生率更高，估计肾小球滤过率小幅但显著下降。在随机分配至FTC/TDF PrEP的参与者中进行的一项巢式病例对照研究中，在12个月时测量的既定肾损伤生物标志物在随后经历这些肾脏终点之一的受试者和随机选择的对照组之间没有显著差异。
We previously reported a higher incidence of non-albumin proteinuria and a small but significant decline in estimated glomerular filtration rate among HIV-negative adults randomized to emtricitabine/ tenofovir disoproxil fumarate pre-exposure prophylaxis (FTC/TDF PrEP) versus placebo. In a nested case-control study among participants randomized to FTC/TDF PrEP, established kidney injury biomarkers measured at 12 months were not significantly different between subjects who subsequently experienced one of these kidney endpoints and randomly selected controls who did not.